Webcasts

Technology Forum: The Next Steps for Pharma Manufacturing Efficiency and Effectiveness

Wednesday, September 15, 2021 at 10am EDTDrug manufacturing demands and increased regulatory oversight are prompting pharmaceutical manufacturers to consider new processes for oral solid dose and aseptically processed drugs. A cross-section of industry experts will offer insight on emerging trends, technologies, and processes in this Technology Forum.

Accelerate Biomedical and Life Sciences Research and Discovery Processes with the Power of Next-Generation Al

Wednesday, September 8, 2021 at 8am EDT| 5am PDT| 1pm BST| 2pm CEST AI has opened up an enormous amount of possibilities for biomedical and life sciences organizations to use growing volumes of data to accelerate and improve upon critical processes that can speed time to value and improve patient outcomes. Learn how next generation AI is revolutionizing how these organizations can deliver innovation and value to patients and overcome the constraints of legacy technology, easier and faster than ever before.

First-in-Human to Commercial: A Microdosing Journey

Thursday, August 26, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST This webcast will explore the benchmark practices for rapid progression from first-in-human to large-scale commercial manufacture for microdosing API. Micro-dosing at a commercial scale made effortless.

Using Artificial Intelligence in a Digital Twin Strategy

Monday, August 23, 2021 at 2pm EDT | 1pm CDT | 11am PDT What do Plato, Roombas, and digital twins for pharma manufacturing have in common? Learn how digital twins, powered by artificial intellingence, can reproduce conditions happening in physical assets to identify and optimize manufacturing process variables, predict outcomes, and empower to bio/pharma companies take action.

Dry Powder Inhalation Delivery of Monoclonal Antibodies

Thursday, July 22, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST Local delivery of monoclonal antibodies to the lung is enabled by spray drying to manufacture stable, respirable dry powders. An inhaled formulation of bevacizumab was effective in vivo, reducing tumor burden in a rat model of non-small cell lung cancer.

Meeting Development and Manufacturing Demands for Emerging Therapies

Wednesday, July 21, 2021 This Technology Forum will explore the current state of commercialization for cell and gene therapies and the patient and physician perspective, as well as the need for technologies, processes, and strategies to ensure competent delivery of these treatments to patients.